Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437713 | 0.94 | CNR1 (0.40) | KDM4CCNR1CNR2ACHEGRM2 | |
| SCHEMBL23467039 | 0.80 | KDM4C (0.40) | KDM4CCNR1CNR2ACHEGRM2 | |
| SCHEMBL29770896 | 0.80 | KDM4C (0.40) | KDM4CCNR1CNR2ACHEGRM2 | |
| SCHEMBL5307216 | 0.78 | CNR2 (0.48) | KDM4CCNR1CNR2ACHEPOLB | |
| SCHEMBL27713903 | 0.77 | KDM4C (0.43) | KDM4CCNR1CFDOPRM1OPRD1 | |
| SCHEMBL5464861 | 0.75 | CNR1 (0.39) | CNR1CNR2ACHEKMT2AGRM4 | |
| SCHEMBL6069757 | 0.74 | CNR2 (0.54) | KDM4CCNR1CNR2ACHEPOLB | |
| SCHEMBL23467068 | 0.74 | CNR2 (0.45) | KDM4CCNR1CNR2GRM2CFD | |
| SCHEMBL5438052 | 0.73 | CNR2 (0.52) | CNR1CNR2ACHEKMT2A | |
| SCHEMBL5297088 | 0.72 | CNR1 (0.49) | CNR1CNR2ACHEPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101098857-A | Nitro indazole derivatives | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265325-A1 | Nitro Indazole Derivatives | NOS3, CYP3A43, NOS2 | KDM4C 2982/4885CNR1 155/4885CNR2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.